Cargando…
Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months
OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationw...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245291/ https://www.ncbi.nlm.nih.gov/pubmed/34187827 http://dx.doi.org/10.1136/bmjopen-2020-048142 |
_version_ | 1783716087011999744 |
---|---|
author | Robertson, Louise J Moore, Julie S Blighe, Kevin Ng, Kok Yew Quinn, Nigel Jennings, Fergal Warnock, Gary Sharpe, Peter Clarke, Mark Maguire, Kathryn Rainey, Sharon Price, Ruth K Burns, William P Kowalczyk, Amanda M Awuah, Agnes McNamee, Sara E Wallace, Gayle E Hunter, David Sager, Steve Chao Shern, Connie Nesbit, M Andrew McLaughlin, James A D Moore, Tara |
author_facet | Robertson, Louise J Moore, Julie S Blighe, Kevin Ng, Kok Yew Quinn, Nigel Jennings, Fergal Warnock, Gary Sharpe, Peter Clarke, Mark Maguire, Kathryn Rainey, Sharon Price, Ruth K Burns, William P Kowalczyk, Amanda M Awuah, Agnes McNamee, Sara E Wallace, Gayle E Hunter, David Sager, Steve Chao Shern, Connie Nesbit, M Andrew McLaughlin, James A D Moore, Tara |
author_sort | Robertson, Louise J |
collection | PubMed |
description | OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationwide serological study. SETTING: Northern Ireland, UK, May 2020–February 2021. PARTICIPANTS: Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. MAIN OUTCOME MEASURES: SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. RESULTS: We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). CONCLUSIONS: Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting. |
format | Online Article Text |
id | pubmed-8245291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82452912021-07-01 Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months Robertson, Louise J Moore, Julie S Blighe, Kevin Ng, Kok Yew Quinn, Nigel Jennings, Fergal Warnock, Gary Sharpe, Peter Clarke, Mark Maguire, Kathryn Rainey, Sharon Price, Ruth K Burns, William P Kowalczyk, Amanda M Awuah, Agnes McNamee, Sara E Wallace, Gayle E Hunter, David Sager, Steve Chao Shern, Connie Nesbit, M Andrew McLaughlin, James A D Moore, Tara BMJ Open Infectious Diseases OBJECTIVE: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. DESIGN: Nationwide serological study. SETTING: Northern Ireland, UK, May 2020–February 2021. PARTICIPANTS: Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. MAIN OUTCOME MEASURES: SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. RESULTS: We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). CONCLUSIONS: Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting. BMJ Publishing Group 2021-06-29 /pmc/articles/PMC8245291/ /pubmed/34187827 http://dx.doi.org/10.1136/bmjopen-2020-048142 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infectious Diseases Robertson, Louise J Moore, Julie S Blighe, Kevin Ng, Kok Yew Quinn, Nigel Jennings, Fergal Warnock, Gary Sharpe, Peter Clarke, Mark Maguire, Kathryn Rainey, Sharon Price, Ruth K Burns, William P Kowalczyk, Amanda M Awuah, Agnes McNamee, Sara E Wallace, Gayle E Hunter, David Sager, Steve Chao Shern, Connie Nesbit, M Andrew McLaughlin, James A D Moore, Tara Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
title | Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
title_full | Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
title_fullStr | Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
title_full_unstemmed | Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
title_short | Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
title_sort | evaluation of the igg antibody response to sars cov-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245291/ https://www.ncbi.nlm.nih.gov/pubmed/34187827 http://dx.doi.org/10.1136/bmjopen-2020-048142 |
work_keys_str_mv | AT robertsonlouisej evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT moorejulies evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT blighekevin evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT ngkokyew evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT quinnnigel evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT jenningsfergal evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT warnockgary evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT sharpepeter evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT clarkemark evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT maguirekathryn evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT raineysharon evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT priceruthk evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT burnswilliamp evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT kowalczykamandam evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT awuahagnes evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT mcnameesarae evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT wallacegaylee evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT hunterdavid evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT sagersteve evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT chaoshernconnie evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT nesbitmandrew evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT mclaughlinjamesad evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months AT mooretara evaluationoftheiggantibodyresponsetosarscov2infectionandperformanceofalateralflowimmunoassaycrosssectionalandlongitudinalanalysisover11months |